La Razón: Un estudio hispano-chino abre la vía para tratar el alzhéimer con nanotecnología
Diseñan nanopartículas que eliminan los tóxicos que dañan al cerebro y restauran habilidades mentales que parecían perdidas.
Group leader
Diseñan nanopartículas que eliminan los tóxicos que dañan al cerebro y restauran habilidades mentales que parecían perdidas.
Amaya Hernández-Vega, a senior researcher at IBEC, will lead one of the two projects selected in the 2024 call for proposals from the Pasqual Maragall Research Programme, which is dedicated to funding research into Alzheimer’s disease and other neurodegenerative conditions. IBEC also celebrates the participation of Jordi Duran, an associate researcher from the Molecular and Cellular Neurobiotechnology group, who will collaborate on the second selected project.
Importante avance médico. Un ensayo científico ha logrado revertir el alzhéimer en ratones a través de una terapia basada en nanotecnología y centrada en el sistema vascular Han logrado una recuperación de las capacidades cognitivas equivalentes a un rejuvenecimiento de unos 20 o 30 años en personas. Declaraciones de Lorena Ruiz Perez, Investigadora del IBEC; Giuseppe Battaglia, Lider Bionica Molecular IBEC.
L’administració de nanopartícules permet netejar toxines del cervell
Diseñan una novedosa técnica centrada en restaurar la salud vascular con inyecciones de nanopartículas. «En una hora se han empezado a ver resultados».
An international team co-led by the Institute for Bioengineering of Catalonia (IBEC) and the West China Hospital Sichuan University (WCHSU) was able to reverse Alzheimer’s in mice after only 3 injections with nanoparticles. The innovative approach to treating the disease focuses on restoring the normal function of the vasculature, rather than acting on neurons or other brain cells, as has usually been done until now. This achievement, published in the Signal Transduction and Targeted Therapy Journal, is a promising step towards an effective treatment for Alzheimer’s disease.
A new study reveals innovative nanotechnology that restored the function of the blood-brain barrier (BBB) to reverse Alzheimer’s in mice.
Injection of nanoparticles “reminds” blood-brain barrier to work properly, allowing brain cells to communicate again
The event, jointly organised by the Institute for Bioengineering of Catalonia (IBEC) and the Institut Químic de Sarrià (IQS), brought together leading scientists from around the world to discuss the latest advances in blood-brain barrier (BBB) research, from its fundamental biology to its role in disease and therapeutic strategies.
Anna Lagunas and Daniel González-Carter, who are both senior researchers at the Institute of Bioengineering of Catalonia (IBEC), will be leading these projects as part of the 2025 edition of the programme. This initiative by the “la Caixa” Foundation aims to accelerate the commercialisation of biomedical innovations to make them available to patients who need them more quickly. The two IBEC projects focus on treating diseases that affect the brain.